Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-018046
Filing Date
2022-05-05
Accepted
2022-05-05 08:16:04
Documents
74
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cccc-10q_20220331.htm   iXBRL 10-Q 2568853
2 EX-31.1 cccc-ex311_8.htm EX-31.1 20646
3 EX-31.2 cccc-ex312_9.htm EX-31.2 20657
4 EX-32.1 cccc-ex321_6.htm EX-32.1 9378
5 EX-32.2 cccc-ex322_7.htm EX-32.2 9275
  Complete submission text file 0001564590-22-018046.txt   9226386

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA cccc-20220331.xsd EX-101.SCH 63385
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE cccc-20220331_cal.xml EX-101.CAL 51935
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cccc-20220331_def.xml EX-101.DEF 171593
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE cccc-20220331_lab.xml EX-101.LAB 444780
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cccc-20220331_pre.xml EX-101.PRE 332303
68 EXTRACTED XBRL INSTANCE DOCUMENT cccc-10q_20220331_htm.xml XML 1808471
Mailing Address 490 ARSENAL WAY SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY SUITE 200 WATERTOWN MA 02472 (617) 231-0700
C4 Therapeutics, Inc. (Filer) CIK: 0001662579 (see all company filings)

EIN.: 475617627 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39567 | Film No.: 22894196
SIC: 2836 Biological Products, (No Diagnostic Substances)